Investor Presentation Full Year 2021
42
Investor presentation Full year 2021
Novo Nordisk global insulin market leadership at 47.1% and the
global insulin volume market grew by 1.0%
North America Operations
Market growth: -0.6%
MS: 38.6%
MS gain/loss¹: -1.0%-p
Sales growth: -9%
Global
Market growth: 1.0%
MS: 47.1%
MS gain/loss¹: -0.1%-p
Sales growth: 1%
International Operations
Market growth: 1.7%
MS: 50.3%
MS gain/loss: 0.1%-p
Sales growth: 6%
USA
Market growth: -0.6%
MS: 38.1%
MS gain/loss¹: -1.3%-p
Sales growth: -9%
Source: IQVIA MAT, Nov 2021 volume figures
Note: Sales growth for full year 2021 at constant exchange rates; Market
shares are for Novo Nordisk and market growth for the total insulin market
1MS gain/loss compared with Nov 2020 reported MS
EMEA: Europe, Middle East and Africa; MS: Market share; ROW: Asia Pacific;
Latin America; MS: Market Share
EMEA
Market growth: 0.1%
MS: 47.6%
MS gain/loss': 0.0%-p
Sales growth: 2%
ROW
Market growth: 2.8%
MS: 57.2%
MS gain/loss: 0.1%-p
Sales growth: 11%
Region China
Market growth: 6.0%
MS: 50.9%
MS gain/loss: 0.3%-p
Sales growth: 8%
Novo NordiskⓇView entire presentation